<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529009</url>
  </required_header>
  <id_info>
    <org_study_id>URT-14/BIO</org_study_id>
    <nct_id>NCT00529009</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Investigation of UDCA in Bile and Serum</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the bile acid composition of cystic bile and serum pharmacoÂ¬kinetics after a 3-week
      treatment with UDCA and to correlate pharmacokinetic parameters of UDCA in bile and serum
      during steady state.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see protocol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UDCA</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PBC or healthy

        Exclusion Criteria:

          -  pathology which does interfere with safety or PK of UDCA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Beuers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beuers</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BA, Schaap FG, Rust C, Beuers U. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol. 2012 Jul;57(1):133-40. doi: 10.1016/j.jhep.2012.02.014. Epub 2012 Mar 10. Erratum in: J Hepatol. 2014 Mar;60(3):684.</citation>
    <PMID>22414767</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <name_title>Dr. Falk Pharma GmbH</name_title>
  </responsible_party>
  <keyword>PK analysis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

